New Data Show Efficacy of Zebinix(TM) in the Treatment o...( PORTO Portugal September 24 /- .....),Health

PORTO, Portugal, September 24 /PRNewswire/ --

- Novel Treatment Also Demonstrated Significant Improvement in Quality of Life and Reduction in Depressive Symptoms

Positive data from three phase III studies presented today at the 8th European Congress of Epileptology, Berlin, Germany, demonstrated that Zebinix(TM) (1) (eslicarbazepine acetate), a novel once daily anti-epileptic agent, significantly reduced the frequency of partial seizures in patients with refractory partial epilepsy, in combination with other anti-epileptic agents.(2,3,4)

Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate.

In addition, treatment with Zebinix(TM) also significantly improved patient quality of life, reduced depressive symptoms and demonstrated sustained reduction in partial seizure frequency during a one-year open label period.(5,6,7)

"When assessing the potential of anti-epileptic agents it is as important to consider the implications on the quality of a patient's day-to-day life, as well as effective seizure control," said Professor E. Ben-Menachem, University of Goteborg, Sweden. "In addition to sustained reductions in seizure frequency, Zebinix(TM) also demonstrated a significant improvement in patient quality of life and reduction in depressive symptoms."

Professor Christian Elger, Director and Head of the Department of Epileptology at the University of Bonn, Germany, added "these data suggest that Zebinix(TM) may become an important treatment option for patients whose seizures are not adequately controlled with existing anti-epileptic agents."

Epilepsy is one of the most common neurological diseases affecting almost one in 100 people.(8) Treatment of partial seizures, the most common type of epilepsy, presents a constant challenge with over half of patients not achieving adequate seizure control with current anti-epileptic drugs.(9)

Zebinix(TM), a new anti-epileptic drug that selectively inh
'/>"/>